iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference
07 août 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference Gosselies, Belgium and Cambridge, MA – August 7, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Present at UBS Global Healthcare Conference
13 mai 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present at UBS Global Healthcare Conference Gosselies, Belgium and Cambridge, MA – May 13, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company developing novel...
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
17 avr. 2019 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer First cohort of patients with advanced cancer now...
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer
17 avr. 2019 02h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Initiates Phase 1/1b Trial with Differentiated Adenosine A2A Antagonist in Patients with Advanced Cancer First cohort of patients with advanced cancer now...
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019
29 mars 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Announces Eight Data Presentations for A2A Receptor Antagonist and Anti-TIGIT Antibody Programs at AACR Annual Meeting 2019 Gosselies, Belgium and...
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer
26 mars 2019 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics Appoints Joanne Jenkins Lager, M.D., as Chief Medical Officer Gosselies, Belgium and Cambridge, MA – March 26, 2019 – iTeos Therapeutics SA, a privately-held biotechnology company...
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in March
05 mars 2019 08h30 HE
|
iTeos Therapeutics SA
Gosselies, Belgium - March 5, 2019 - iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today announced that Michel Detheux, Ph.D., Chief Executive Officer of...
iTeos Therapeutics to Participate in Upcoming Conferences in November
07 nov. 2018 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming Conferences in November Gosselies, Belgium – November 7, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies,...
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting
06 nov. 2018 08h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Present Data at 2018 SITC Annual Meeting Gosselies, Belgium – November 6, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer immunotherapies, today...
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September
29 août 2018 07h00 HE
|
iTeos Therapeutics SA
iTeos Therapeutics to Participate in Upcoming U.S. Conferences in September Gosselies, Belgium – August 29, 2018 – iTeos Therapeutics SA, a biotechnology company developing novel cancer...